Joshua S Ostrenga
Overview
Explore the profile of Joshua S Ostrenga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ostrenga J, Robinson K, Brown A, Goss C, Cromwell E
J Cyst Fibros
. 2024 Nov;
24(1):183-186.
PMID: 39500648
We conducted a descriptive analysis of people with CF 40 years of age and older using CF Foundation Patient Registry data from 2022 to provide a current estimate of the...
2.
Schechter M, Ostrenga J, Cromwell E, Ren C, Fink A, Sanders D, et al.
Pediatr Pulmonol
. 2024 Jul;
59(12):3212-3220.
PMID: 38995116
Background: The benefit of antibiotic treatment of acute drops in FEV percent predicted (FEVpp) has been clearly established, but data from the early 2000s showed inconsistent treatment. Further, there is...
3.
Carroll B, Ostrenga J, Fink A, Antos N, Cromwell E, Ren C
Pediatr Pulmonol
. 2024 Mar;
59(6):1606-1613.
PMID: 38477633
Background And Objectives: There are limited data on cystic fibrosis (CF) transmembrane conductance regulator-related metabolic syndrome (CRMS) outcomes beyond infancy. The goal of this study was to analyze outcomes of...
4.
Alshehri M, Ramos K, Sykes J, Ma X, Stanojevic S, Quon B, et al.
Clin Transplant
. 2023 Aug;
37(11):e15097.
PMID: 37563332
Introduction: Re-transplant is an option for those who develop end-stage lung disease due to rejection; however, little data exist following re-transplantation in cystic fibrosis (CF). Methods: Data from the Canadian...
5.
Ostrenga J, Brown A, Todd J, Elbert A, Fink A, Faro A, et al.
Ann Epidemiol
. 2023 Aug;
86:98-103.e5.
PMID: 37549758
Purpose: Deaths among those lost to follow-up (LTFU) in the Cystic Fibrosis Foundation Patient Registry (CFFPR) are critically important to the epidemiology of cystic fibrosis (CF). Unreported deaths could impact...
6.
Albaiz F, Ramos K, Sykes J, Stanojevic S, Ma X, Quon B, et al.
Liver Transpl
. 2023 Aug;
30(3):302-310.
PMID: 37530842
There is paucity of literature on the health outcomes following liver transplantation (LT) in people with cystic fibrosis (pwCF). We aim to evaluate changes in lung function following LT in...
7.
Cromwell E, Ostrenga J, Todd J, Elbert A, Brown A, Faro A, et al.
J Cyst Fibros
. 2023 Mar;
22(3):436-442.
PMID: 36922288
Background: The Cystic Fibrosis Foundation Patient Registry (CFFPR) collects data on individuals with cystic fibrosis (CF) in the United States (US). In 2012, the US CF population was estimated at...
8.
Szczesniak R, Andrinopoulou E, Su W, Afonso P, Burgel P, Cromwell E, et al.
Ann Am Thorac Soc
. 2023 Mar;
20(7):958-968.
PMID: 36884219
Studies estimating the rate of lung function decline in cystic fibrosis have been inconsistent regarding the methods used. How the methodology used impacts the validity of the results and comparability...
9.
Ramos K, Sykes J, Stanojevic S, Ma X, Ostrenga J, Fink A, et al.
Chest
. 2021 Apr;
160(3):843-853.
PMID: 33878343
Background: Understanding how health outcomes differ for patients with advanced cystic fibrosis (CF) lung disease living in the United States compared with Canada has health policy implications. Research Question: What...
10.
Stephenson A, Ramos K, Sykes J, Ma X, Stanojevic S, Quon B, et al.
J Heart Lung Transplant
. 2021 Jan;
40(3):201-209.
PMID: 33386232
Background: Previous literature in cystic fibrosis (CF) has shown a 10-year survival gap between Canada and the United States (US). We hypothesized that differential access to and survival after lung...